Resveratrol Ameliorated Hyperlipidemia: Association with Modulation of the Gut Microbiota and Bile Acid Metabolism
Nutrients · 21.07.2026 · 18 (14) · 2384
DOI: 10.3390/nu18142384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 21.07.2026. Verfasst von Ruiying Luo und 4 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutic…. Hauptthemen laut MEDLINE: Resveratrol, Hyperlipidemias, Gastrointestinal Microbiome, Bile Acids and Salts. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Institute of Science and Technology.
Abstract (Originalsprache)
Background
Hyperlipidemia represents a pivotal risk factor for multiple cardiovascular and metabolic diseases, creating an urgent demand for safe, effective novel therapeutic interventions. Resveratrol (RES), a natural plant polyphenol, has exhibited great potential as a hypolipidemic agent for hyperlipidemia treatment.
Methods
In this work, we established a high-fat diet (HFD)-induced hyperlipidemic mouse model to systematically investigate the lipid-regulating efficacy of RES.
Results
Oral administration of RES significantly decreased serum levels of total cholesterol and low-density lipoprotein cholesterol, while markedly increasing high-density lipoprotein cholesterol concentrations. Histopathological analyses further demonstrated that RES alleviated HFD-induced hepatic and ileal injury. Moreover, RES significantly decreased the circulating levels of several bile acids (BAs), including taurodeoxycholic acid, taurolithocholic acid, lithocholic acid, and tauro-(α + β)-muricholic acid. RES also ameliorated HFD-induced gut microbial dysbiosis, as evidenced by a reduction in the Firmicutes/Bacteroidetes ratio, increased relative abundances of non_f_Muribaculaceae, Lactobacillus, Ileibacterium, and Bacteroides, and decreased abundances of Lachnospiraceae_NK4A136_group and unclassified f_Lachnospiraceae. Spearman correlation analysis revealed significant associations between gut microbial taxa and BA profiles, suggesting that coordinated regulation of the gut microbiota and BA metabolism contributes to the hypolipidemic effects of RES.
Conclusions
Collectively, RES alleviates HFD-induced hyperlipidemia by remodeling gut microbiota composition and restoring bile acid metabolic homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.
ORCID-Profile: Ruiying Luo, Qing Peng, Su Wu, Shuwen Liu
Förderung
- National Natural Science Foundation of China
- Guangzhou Institute of Science and Technology
Zitieren
APA
Luo, R., Peng, Q., Wu, S., Liu, S., & Wang, C. (2026). Resveratrol Ameliorated Hyperlipidemia: Association with Modulation of the Gut Microbiota and Bile Acid Metabolism. Nutrients, 18(14), 2384. https://doi.org/10.3390/nu18142384
Vancouver
Luo R, Peng Q, Wu S, Liu S, Wang C. Resveratrol Ameliorated Hyperlipidemia: Association with Modulation of the Gut Microbiota and Bile Acid Metabolism. Nutrients. 2026;18(14):2384. doi:10.3390/nu18142384
BibTeX
@article{Luo2026,
author = {Luo, Ruiying and Peng, Qing and Wu, Su and Liu, Shuwen and Wang, Chan},
title = {Resveratrol Ameliorated Hyperlipidemia: Association with Modulation of the Gut Microbiota and Bile Acid Metabolism},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {14},
pages = {2384},
doi = {10.3390/nu18142384}
}
EUVIMED